Skip to main
CARL
CARL logo

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed Inc. is projected to experience substantial growth, with annual utilization per surgeon expected to rise from 5.8 in 2024 to approximately 9.7 over the next three years, supported by an expanding physician base of around 400 doctors. Lumbar revenue is estimated to reach around $121 million by 2028, alongside the anticipated introduction of Cervical solutions, which is expected to comprise 15% of overall revenue by the same year. Furthermore, the company's R&D investments are expected to yield significant returns, with incremental revenues outpacing the growth in R&D expenses, contributing to a projected revenue compound annual growth rate (CAGR) exceeding 50% from 2024 to 2028.

Bears say

Carlsmed Inc faces several challenges that could negatively impact its stock performance. The anticipated decline in average selling price per case, driven by an increasing mix of lower-priced cervical procedures, poses a risk to revenue projections, particularly as the company competes against larger players with broader portfolios. Additionally, potential slower adoption of its AI-enabled aprevo technology by surgeons, coupled with reimbursement changes that could adversely affect hospital economics, may hinder growth and put downward pressure on pricing.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.